JP2014172901A - Fat absorption inhibitor - Google Patents
Fat absorption inhibitor Download PDFInfo
- Publication number
- JP2014172901A JP2014172901A JP2013058948A JP2013058948A JP2014172901A JP 2014172901 A JP2014172901 A JP 2014172901A JP 2013058948 A JP2013058948 A JP 2013058948A JP 2013058948 A JP2013058948 A JP 2013058948A JP 2014172901 A JP2014172901 A JP 2014172901A
- Authority
- JP
- Japan
- Prior art keywords
- fat absorption
- absorption inhibitor
- composition
- food
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
本発明は脂肪吸収抑制を目的とした組成物、及び該組成物を含む飲食品、医薬品または飼料に関する。 The present invention relates to a composition for the purpose of suppressing fat absorption, and a food, drink, pharmaceutical product or feed containing the composition.
近年、食生活の欧米化や運動不足、ストレスなどの影響により、肥満をはじめとする生活習慣病患者が増加している。平成２１年度国民健康・栄養調査によると、２０歳以上の日本における肥満者の割合は、男性３０．５％、女性２０．８％、全体で２５．７％であり、実におよそ４人に１人が肥満であるということになる。（日本ではＢＭＩ２５．０以上を肥満と判定する）肥満とは体内の脂肪組織が過剰に蓄積した状態を言う。肥満を体脂肪分布から分類すれば、内臓脂肪型肥満と皮下脂肪型肥満に分けられる。特に内臓脂肪の蓄積は、脂質代謝異常症、耐糖能異常、高血圧を引き起こし、メタボリックシンドロームの成因として注目されている。これらの肥満を予防・改善するために抗肥満作用を有する新規食品素材の探索を行い、効果の高い素材が求められている。 In recent years, the number of patients with lifestyle-related diseases such as obesity has increased due to the influence of westernization of eating habits, lack of exercise, and stress. According to the 2009 National Health and Nutrition Survey, the proportion of obese people in Japan over 20 years old is 30.5% for men and 20.8% for women, totaling 25.7%. A person is obese. (In Japan, BMI 25.0 or higher is determined as obesity) Obesity refers to a state in which adipose tissue in the body has accumulated excessively. If obesity is classified from body fat distribution, it can be divided into visceral fat type obesity and subcutaneous fat type obesity. In particular, accumulation of visceral fat causes dyslipidemia, impaired glucose tolerance, and hypertension, and is attracting attention as a cause of metabolic syndrome. In order to prevent and ameliorate these obesity, new food materials having anti-obesity action are searched for, and highly effective materials are required.
シラタマカズラ（学名Ｐｓｙｃｈｏｔｒｉａ ｓｅｒｐｅｎｓ Ｌ）は常緑のアカネ科ボチョウジ属つる植物で、九州南部、沖縄、中国に分布する。葉は対生し長さ２〜４．５ｃｍ枝先に小さい白色花をつけ、秋に白い球状の果実がなる。シラタマカズラは中国生薬として絡石籐の一部を利用し、抗炎症、鎮痛など効果がある。特許は抗酸化剤、抗炎症剤である。しかしながら、シラタマカズラに脂肪吸収抑制効果があるという報告はまだされていない。 Shiratamakazura (scientific name: Psychotoria serpens L) is an evergreen Rubiaceae genus vine, distributed in southern Kyushu, Okinawa, and China. The leaves are opposite and have a length of 2 to 4.5 cm. A small white flower is attached to the tip of the branch, and a white spherical fruit is formed in autumn. Shiratamakazura uses a part of the rattan stone rattan as a Chinese herbal medicine and has effects such as anti-inflammation and analgesia. Patents are antioxidants and anti-inflammatory agents. However, no report has been made that white-faced pods have an effect of suppressing fat absorption.
本発明は、脂肪吸収抑制作用を有する組成物を提供し、ひいては該組成物を含有する飲食品、医薬品又は飼料を提供することにある。 An object of the present invention is to provide a composition having a fat absorption inhibitory action, and thus to provide a food, drink, medicine or feed containing the composition.
上記の課題を解決するために鋭意検討を重ねた結果、シラタマカズラに顕著な脂肪吸収抑制作用があることを見出した。すなわち本発明は、以下の構成を有する。
（１）シラタマカズラの成分を含有することを特徴とする脂肪吸収抑制組成物。
（２）上記（１）に記載の組成物を含有する飲食品、医薬品又は飼料。As a result of intensive studies in order to solve the above-mentioned problems, it has been found that white-tailed quail has a remarkable fat absorption inhibitory effect. That is, the present invention has the following configuration.
(1) A fat absorption inhibiting composition comprising a component of white-faced wig.
(2) Food / beverage products, pharmaceuticals or feed containing the composition according to (1) above.
本発明により、シラタマカズラの成分を含有することを特徴とする脂肪吸収抑制組成物、及び該組成物を含有する飲食品、医薬品又は飼料を提供することができる。 According to the present invention, it is possible to provide a fat absorption inhibitory composition characterized by containing a component of white-faced wig, and a food, beverage, medicine or feed containing the composition.
本発明に関わるシラタマカズラは、植物全体、又は葉部をそのまま用いてもよく、これらを乾燥した乾燥体、もしくは乾燥後粉砕した粉末を用いることもできる。また、これらを水、又はアルコールなどの有機溶媒で抽出した抽出物を用いることもできる。 As for the white-faced wig of the present invention, the whole plant or the leaf part may be used as it is, and a dried product obtained by drying these or a powder obtained by pulverizing after drying can also be used. Moreover, the extract which extracted these with organic solvents, such as water or alcohol, can also be used.
本発明に関わる脂肪吸収抑制剤を製造するには、上記の方法で製造したシラタマカズラの成分を用いることができ、常法に従って公知の医薬用無毒性担体と組み合わせて製剤化すればよい。本発明に関わる脂肪吸収抑制剤は、種々の剤型での投与が可能であり、例えば、経口投与剤としては錠剤、顆粒剤、散剤、カプセル剤、ソフトカプセル剤などの固形剤、溶液剤、懸濁剤、乳化剤等の液剤、凍結乾燥剤等があげられ、これらの製剤は製剤上の常套手段により調製することができる。上記医薬用無毒性担体としては、例えば、グルコース、乳糖、ショ糖、でんぷん、マンニトール、デキストリン、脂肪酸グリセリド、ポリエチレングリコール、ヒドロキシエチルでんぷん、エチレングリコール、ポリオキシエチレンソルビタン脂肪酸エステル、アミノ酸、アルブミン、水、生理食塩水などが挙げられる。また、必要に応じて安定化剤、滑沢剤、湿潤剤、乳化剤、結合剤等の慣用の添加剤を適宜添加することができる。本発明に関わる脂肪吸収抑制剤において、脂肪吸収抑制剤成分の投与量は、患者の年齢、体重、症状、疾患の程度、投与スケジュール、製剤形態等により、適宜選択、決定されるが、例えば、一日当たり生葉等価量として０．０１ｍｇ−１０ｇ／ｋｇ体重程度とされ、一日数回に分けて投与してもよい。 In order to produce the fat absorption inhibitor according to the present invention, the component of white-tailed quail produced by the above method can be used, and it may be formulated in combination with a known non-toxic pharmaceutical carrier according to a conventional method. The fat absorption inhibitor according to the present invention can be administered in various dosage forms. For example, oral administration includes solid agents such as tablets, granules, powders, capsules, soft capsules, solutions, suspensions, and the like. Examples thereof include suspensions, liquids such as emulsifiers, freeze-drying agents and the like, and these preparations can be prepared by conventional means in preparation. Examples of the non-toxic pharmaceutical carrier include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, albumin, water, Examples thereof include physiological saline. In addition, conventional additives such as stabilizers, lubricants, wetting agents, emulsifiers, binders and the like can be appropriately added as necessary. In the fat absorption inhibitor according to the present invention, the dose of the fat absorption inhibitor component is appropriately selected and determined according to the patient's age, body weight, symptoms, degree of disease, administration schedule, formulation form, etc. The equivalent amount of fresh leaves per day is about 0.01 mg-10 g / kg body weight, and may be administered in several divided doses per day.
また、シラタマカズラは、毒性を有することは報告されていないことから、脂肪吸収抑制を目的とした飲食品として摂取することもできる。シラタマカズラの成分は、特定保健用食品、栄養機能食品、又は健康食品等として位置付けることができる。機能性食品としては、例えば、シラタマカズラの成分に適当な助剤を添加した後、慣用の手段を用いて、食用に適した状態、例えば、顆粒状、粒状、錠剤、カプセル剤、ソフトカプセル剤、ペースト状等に形成したものを用いることができる。この飲食品は、そのまま食用に供してもよく、また種々の食品（例えばハム、ソーセージ、かまぼこ、ちくわ、パン、バター、粉乳、菓子など）に添加して使用したり、水、酒類、果汁、牛乳、清涼飲料水等の飲物に添加して使用したりしてもよい。かかる食品の形態における本発明のシラタマカズラの成分の摂取量は、年齢、体重、症状、疾患の程度、食品の形態等により適宜選択・決定されるが、例えば、一日当たり生葉等価量として０．０１ｍｇ−１０ｇ／ｋｇ体重程度とされ、一日数回に分けて投与してもよい。 In addition, Shiratakakazura has not been reported to be toxic, so it can be taken as a food or drink for the purpose of inhibiting fat absorption. The component of Shiratamakazura can be positioned as a food for specified health use, a nutritional functional food, a health food, or the like. As functional food, for example, after adding a suitable auxiliary agent to the component of white-faced quail, using a conventional means, a state suitable for food, for example, granular, granular, tablet, capsule, soft capsule, What was formed in the paste form etc. can be used. This food and drink may be used for food as it is, and added to various foods (for example, ham, sausage, kamaboko, chikuwa, bread, butter, milk powder, confectionery, etc.), water, alcoholic beverages, fruit juice, It may be used by adding to drinks such as milk and soft drinks. The intake amount of the component of the present invention in such a form of food is appropriately selected and determined according to age, weight, symptoms, degree of disease, form of food, etc. The dosage may be about 01 mg-10 g / kg body weight, and may be administered in several divided doses per day.
以下に本発明をより詳細に説明するために実施例を挙げるが、本発明はこれらによって何ら限定されるものではない。 Examples are given below to describe the present invention in more detail, but the present invention is not limited by these.
実施例 シラタマカズラ抽出物の脂肪吸収抑制活性
シラタマカズラ抽出物の脂肪吸収抑制効果を調べるために以下の実験を行った。すなわち７週齢、雌のｄｄＹマウス（ｎ＝８）に尾採血を行った後、シラタマカズラ抽出物（１０００ｍｇ／１０ｍｌ／ｋｇ）とコーン油８ｍｌ／ｋｇをそれぞれに経口投与して、経時的に尾採血を行った。コントロール群にはＤ．Ｗ．１０ｍｌ／ｍｇとコーン油８ｍｌ／ｋｇをそれぞれに経口投与し、０、２、４、６、８時間後に採血して、血中中性脂肪濃度を測定した。その結果を表１に示す。数値は平均値±標準誤差（ｍｇ／ｄｌ）。カッコ内はシラタマカズラ抽出群がコントロールに対する有意差を示す。（ｓｔｕｄｅｎｔのＴ−ＴＥＳＴ）Examples Fat Absorption Inhibitory Activity of Shiratakakazura Extract The following experiment was conducted in order to examine the fat absorption inhibiting effect of Shiratakakazura extract. That is, tail blood collection was performed on 7-week-old female ddY mice (n = 8), and then a white-tailed quail extract (1000 mg / 10 ml / kg) and corn oil 8 ml / kg were orally administered to each of the mice over time. Tail blood was collected. In the control group, D.C. W. 10 ml / mg and corn oil 8 ml / kg were orally administered to each, and blood was collected after 0, 2, 4, 6, 8 hours, and the blood neutral fat concentration was measured. The results are shown in Table 1. Numerical values are mean ± standard error (mg / dl). In parentheses, the Shiratamakazura extraction group shows a significant difference from the control. (Student T-TEST)
この結果からシラタマカズラ抽出物が脂肪吸収を抑制することが示された。From this result, it was shown that Shirotamaka quail extract suppresses fat absorption.
本発明により、シラタマカズラの成分を含有することを特徴とする脂肪吸収抑制組成物及び該組成物を含有する飲食品、医薬品又は飼料を提供することが可能となった。According to the present invention, it is possible to provide a fat absorption inhibitory composition characterized by containing a component of white-faced wig and a food / beverage product, pharmaceutical or feed containing the composition.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013058948A JP2014172901A (en) | 2013-03-05 | 2013-03-05 | Fat absorption inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013058948A JP2014172901A (en) | 2013-03-05 | 2013-03-05 | Fat absorption inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2014172901A true JP2014172901A (en) | 2014-09-22 |
Family
ID=51694504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013058948A Pending JP2014172901A (en) | 2013-03-05 | 2013-03-05 | Fat absorption inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2014172901A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11844762B2 (en) | 2020-02-25 | 2023-12-19 | Pharma Foods International Co .. Ltd. | Fat absorption inhibiting agent, food and defatted sesame seeds, and method for inhibiting obesity |
-
2013
- 2013-03-05 JP JP2013058948A patent/JP2014172901A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11844762B2 (en) | 2020-02-25 | 2023-12-19 | Pharma Foods International Co .. Ltd. | Fat absorption inhibiting agent, food and defatted sesame seeds, and method for inhibiting obesity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101661793B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| JP2013501778A (en) | HEALTH SUPPLEMENTAL, FEED, PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING THE SAME CONTAINING CHIASEED AND MACA | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR101507427B1 (en) | Pharmaceutical composition and healthy food for alleviating disorders caused by the andropause | |
| KR101731859B1 (en) | A composition for the prevention or treatment of abnormal weight loss comprising Citrus Unshiu Peel extract | |
| JP2007230987A (en) | Anti-obestic agent | |
| KR102470155B1 (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
| JP2014172901A (en) | Fat absorption inhibitor | |
| JP6757995B2 (en) | Oral composition | |
| JP2012131760A (en) | Fatty acid absorption inhibitor | |
| JP7185990B2 (en) | Adiponectin secretion promoter, adipocyte differentiation promoter, and pharmaceutical composition, food and feed containing them | |
| JP2019176828A (en) | Oral composition | |
| JP6273440B2 (en) | GLP-1 production promoter, DPPIV inhibitor and glucose absorption inhibitor | |
| JP7452874B2 (en) | Oral composition | |
| JP2020063216A (en) | Oral composition | |
| KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| US20230124668A1 (en) | Psychological fatigue preventer or improver | |
| JP5048258B2 (en) | Rebound inhibitor | |
| JP2007230989A (en) | Endurance enhancing and anti-fatigue agent | |
| JP2021161069A (en) | Postprandial blood triglyceride increase inhibitor | |
| KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract | |
| JP2020191902A (en) | Oral composition | |
| JP4469406B1 (en) | Blood cholesterol lowering agent | |
| JP5706142B2 (en) | Blood glucose lowering agent, visceral fat accumulation inhibitor, TG lowering agent, faecal fat excretion promoter containing ethanol extract of Fuyubodaiju flower as an active ingredient | |
| JP2023063521A (en) | oral composition |